Brief: Chinook Therapeutics Announces Partnership With Ionis To Develop Antisense Therapy For Rare, Severe Chronic Kidney Disease
16/05/2023 13:31
May 16 (Reuters) - Chinook Therapeutics Inc KDNY.O :
* CHINOOK THERAPEUTICS ANNOUNCES PARTNERSHIP WITH IONIS TO
DEVELOP
ANTISENSE THERAPY FOR RARE, SEVERE CHRONIC KIDNEY DISEASE
* CHINOOK THERAPEUTICS - WILL PAY IONIS UNDISCLOSED UPFRONT
PAYMENT AS WELL AS POTENTIAL DEVELOPMENT AND REGULATORY
MILESTONE PAYMENTS AND ROYALTIES
* CHINOOK THERAPEUTICS - IONIS TO BE RESPONSIBLE FOR
IND-ENABLING
TOXICOLOGY STUDIES & CO TO BE RESPONSIBLE FOR CLINICAL
DEVELOPMENT & COMMERCIALIZATION
Source text for Eikon: ID:nGNX8gfB5K
Further company coverage: KDNY.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Chinook Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Chinook Therapeutics
Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Chinook Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart
Brief: Muddy Waters- Remains Short On Chinook Therapeutics Inc